Alessandro D.
- Country
- Italy
- Department
- Oncology
Research Overview
- Phase II Open‑Label Study of Cemiplimab Plus Platinum‑Gemcitabine in Treatment‑Naïve Advanced Squamous NSCLC Selected by Low Cytidine Deaminase Activity
- A Phase III Double-Blind, Placebo-Controlled Study of Adjuvant Durvalumab in Resected Stage IB-IIIA Non-Small Cell Lung Cancer with PD-L1 Expression ≥25%
Data & Insights
Has run more than one trial at 2 of 112 partner sites.
Specializations
Thoracic Oncology
This investigator specializes in the treatment of non-small cell lung cancer, with particular emphasis on early-stage disease management. Their research focus includes surgical oncology and adjuvant therapy approaches for resected lung cancer.
- Early-stage lung cancer treatment
- Post-surgical therapeutic strategies
- Immuno-oncology applications
Their expertise extends to the investigation of targeted treatments for specific patient populations with resectable lung cancer.
Precision Medicine
The investigator's work encompasses biomarker-driven treatment approaches, particularly focusing on PD-L1 expression in lung cancer patients. Their research interests include patient stratification based on molecular characteristics.
- Molecular profiling
- Personalized treatment selection
- Biomarker analysis
Their work contributes to advancing personalized therapeutic strategies in thoracic oncology.
Clinical Research
This investigator focuses on adjuvant immunotherapy development for early-stage cancer treatment. Their expertise includes evaluation of novel therapeutic approaches in the post-surgical setting.
- Disease-free survival assessment
- Post-operative care optimization
- Long-term patient outcomes
Their research aims to improve treatment outcomes for patients with resected lung cancer.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.